Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Patiromer - Relypsa

Drug Profile

Patiromer - Relypsa

Alternative Names: ILY-105; Patiromer acetate; Patiromer calcium; Patiromer sorbitex calcium; RLY-105; RLY-5016; RLY-5016S; Veltassa; ZG 801

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Relypsa
  • Developer Relypsa; Vifor Fresenius Medical Care Renal Pharma; Zeria
  • Class Polymers
  • Mechanism of Action Potassium binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperkalaemia

Most Recent Events

  • 10 May 2019 Efficacy and safety data from the phase II AMBER trial for Hyperkalaemia released by Vifor Pharma
  • 25 Apr 2019 Relypsa and Vifor Pharma initiate enrolment in the phase III DIAMOND trial for Hyperkalemia in USA (NCT03888066)
  • 14 Mar 2019 Relypsa and Vifor Pharma plans the DIAMOND phase III trial for Hyperkalaemia in H1 2019 (NCT03888066)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top